Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers
Authors:
- Jun Soo KwonJKJun Soo Kwon
- Yong-Wook ShinYSYong-Wook Shin
- Jae Sung LeeJLJae Sung Lee
- Won Jun KangWKWon Jun Kang
- Hang Joon JoHJHang Joon Jo
- Jong-Min LeeJLJong-Min Lee
- Kyung-Sang YuKYKyung-Sang Yu
- Do-Hyung KangDKDo-Hyung Kang
- Joo-Youn ChoJoo-Youn Cho
- In-Jin JangIJIn-Jin Jang
- Sang-Goo ShinSSSang-Goo Shin
- 1 February 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 18 (2) , 91-97
Abstract
The Taq1A polymorphism in the dopamine D2 receptor (DRD2) gene has been reported to be associated with the pharmacodynamics of antipsychotic drugs. We investigated the metabolic response of glucose in the brain to aripiprazole in relation to the DRD2 Taq1A polymorphism. Twenty healthy male volunteers were recruited and were divided into two groups of 10 participants, according to their DRD2 genotypes (A1A1, n=10; A2A2, n=10). The volunteers received single oral doses of aripiprazole (10 mg) and a placebo, following a single-blind, placebo-controlled, randomized, two-way crossover study design. Brain glucose metabolism was assessed using positron emission tomography, scanned with 18F-fluorodeoxyglucose 12 h after the administration of the drug or placebo. In voxel-based analysis using SPM2, volunteers with the A2A2 genotype showed decreased metabolism in the right middle frontal gyrus, the left middle and inferior frontal gyrus, the right and left inferior temporal gyrus, and the right cingulate gyrus, and increased metabolism in the pons. In contrast, volunteers with the A1A1 genotype exhibited increased metabolism in the right caudate head, and no brain region showed decreased metabolism. In a region-of-interest analysis, significant interactions between drug and genotype were observed in the right medial orbitofrontal gyrus and the left caudate nucleus. This suggests that DRD2 Taq1A polymorphism status may be associated with the clinical response to aripiprazole.Keywords
This publication has 33 references indexed in Scilit:
- Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary studyHuman Psychopharmacology: Clinical and Experimental, 2006
- Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazoleInternational Journal of Neuropsychopharmacology, 2006
- Worsening Schizoaffective Disorder With AripiprazoleAmerican Journal of Psychiatry, 2004
- Pharmacogenetics of Psychotropic Drug ResponseAmerican Journal of Psychiatry, 2004
- Worsened Agitation With AripiprazoleThe Journal of Clinical Psychiatry, 2004
- Aripiprazole possibly worsens psychosisInternational Clinical Psychopharmacology, 2004
- Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective DisorderArchives of General Psychiatry, 2003
- Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trialsSchizophrenia Research, 2003
- D1 receptor alleles predict PET metabolic correlates of clinical response to clozapineMolecular Psychiatry, 2003
- Association of Short-Term Response to Haloperidol Treatment With a Polymorphism in the Dopamine D2 Receptor GeneAmerican Journal of Psychiatry, 2001